Top Markets
Coin of the day
Frequency Therapeutics, Inc. Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc.

FREQ
株式のランク #32262
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company... Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
株価
$0.2996
最終同期: 2023-11-03
時価総額
$10.58M
変化(1日)
5.94%
変化(1年)
0.00%
US
取引 Frequency Therapeutics, Inc. (FREQ)

カテゴリー

Frequency Therapeutics, Inc.(FREQ)のEPS
2026 時点のEPS TTM: 0
Frequency Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Frequency Therapeutics, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS